NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) —
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
- RayzeBio, Inc. (Nasdaq: RYZB), relating to its proposed sale to Bristol-Myers Squibb Co. Under the terms of the agreement, RYZB shareholders are expected to receive $62.50 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/rayzebio-inc. It is free and there is no cost or obligation to you.
- Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/theseus-pharmaceuticals-inc. It is free and there is no cost or obligation to you.
- Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/ambrx-biopharma-inc. It is free and there is no cost or obligation to you.
- CapStar Financial Holdings, Inc. (Nasdaq: CSTR), relating to its proposed sale to Old National Bancorp. Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own. Click here for more information: https://www.monteverdelaw.com/case/capstar-financial-holdings-inc. It is free and there is no cost or obligation to you.
About Monteverde & Associates PC
We are a national class action securities and consumer litigation law firm that has recovered millions of dollars for shareholders and is committed to protecting investors and consumers from corporate wrongdoing. Monteverde & Associates lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions, whereby they protect investors by recovering money and remedying corporate misconduct. Mr. Monteverde, who leads the legal team at the firm, has been recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019 and a Super Lawyers Honoree in Securities Litigation in 2022-2023. He has also been selected by Martindale-Hubbell as a 2017-2023 Top Rated Lawyer. Our firm’s recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, over the years the firm has recovered or secured over a dozen cash common funds for shareholders in mergers & acquisitions class action cases.
If you own common stock in any of the above listed companies and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341
Attorney Advertising. (C) 2023 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
- ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025 - June 17, 2025
- Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress - June 17, 2025
- ANNUAL RESULTS 2024-25 FOR THE LEXIBOOK GROUP: ANNUAL REVENUE AT €74.0M (+26.3%). EBIT AND NET INCOME UP, AT €8.1M AND €7.4M RESPECTIVELY, THANKS TO AN EXCEPTIONAL COMBINATION OF POSITIVE FACTORS. UNCERTAIN OUTLOOK FOR THE 2025-26 FISCAL YE - June 17, 2025
